BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines and immunotherapy to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.

Vaccine Pipeline

BlueWillow’s intranasal vaccine platform has successfully demonstrated safety and immunogenicity in humans as well as safety and efficacy in primary animal models for several diseases.  A successful phase 1 clinical trial in Anthrax was recently completed.  Clinical trials for an intranasal Covid-19 booster as well as therapeutic HSV-2 and pandemic flu vaccines are planned for the near future.

The company has also demonstrated that its adjuvant technology platform shifts the immune response in food allergy from inflammatory (Th2) to protective (Th1) enabling a durable, intranasal immunotherapy candidate.   GMP manufacturing of clinical materials is ongoing for the lead Peanut Allergy program leading to near-term clinical development.

BlueWillow Biologics: Vaccine Development Pipeline

BlueWillow's Vaccine Development Pipeline